# A treatment matters when your joint feels and works better *Regenerative Medicine Glendale | What Treatment Claims Mean* > Regenerative medicine Glendale claims are easier to judge when soreness, movement, cost, and scan findings stay separate. Glendale traffic around big events can turn a short drive into a tiring wait. Joint care can waste time in much the same way when a sales claim isn't clear. You don't need to study charts to ask whether a treatment helped. Find out whether people moved more easily, hurt less, or slept better than those getting other care. A changed scan is useful information, but it isn't the same as a better day. Keep the question close to your own life. ## Before-and-after praise doesn't give the whole answer Joint soreness rises and falls even when nothing new is done, since rest, attention, and hope can change how a person feels for a time without fixing the cause. That's why a fair test compares one treatment with another choice. When the groups improve equally, the new treatment may not deserve the credit. You don't need the name of every study. Ask what changed for daily movement, how long any benefit remained, and whether the other group changed too. Finish by checking how closely the study group matches your joint. The useful result is one you could notice. ## If the soreness doesn't settle, ask the clinic for plain facts Regenerative treatments use prepared blood or another kind of body material at a clinic. When QC Kinetix discusses one, ask what it is made from and why it may fit your joint. Medical providers are licensed team members responsible for the joint exam and care. They can also tell you when an option isn't a good match. Don't let a scan claim take the place of a talk about walking, sleep, or work. Ask about the complete cost before you agree, including any return visits that may be proposed. Clear limits are part of an honest answer. ## Sources 1. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). *FDA*, 2020. 2. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative. Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 3. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature medicine*, 2023. DOI: 10.1038/s41591-023-02632-w. 4. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit. Awad G, et al. — [Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/41863718/). *Clinical rheumatology*, 2026. DOI: 10.1007/s10067-026-08042-w. 5. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it. Sadeghirad B, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021. 6. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other. Eckstein F, et al. — [Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.](https://pubmed.ncbi.nlm.nih.gov/33962962/). *Annals of the rheumatic diseases*, 2021. DOI: 10.1136/annrheumdis-2020-219181. 7. OA-11, a 56-week phase 3 double-blind placebo-controlled trial, randomized 513 knee OA patients (KL 2-3) to a single intra-articular injection of the Wnt-pathway modulator lorecivivint or vehicle placebo. Lorecivivint MISSED its primary endpoint: 12-week pain NRS change was -2.24 with drug versus -2.49 with placebo (p=0.185), no other endpoint showed a discernible treatment effect, and neither group lost meaningful medial joint space over 52 weeks. Even a purpose-built, well-funded disease-modifying candidate has not beaten a placebo injection. Yazici Y, et al. — [A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/39808286/). *Clinical and experimental rheumatology*, 2025. DOI: 10.55563/clinexprheumatol/hjt118. 8. A meta-analysis of 14 placebo cohorts from 13 Level-1 knee OA injection trials (1,076 patients, KL 1-4) measured what the SALINE arms did. Intra-articular normal saline produced a statistically significant VAS pain improvement at 3 months (MD 12.10) and a larger one at 6 months (MD 16.62), reaching clinically meaningful thresholds. Any uncontrolled report of 'my injection worked' has to clear this bar before it means anything about the injectate. Saltzman BM, et al. — [The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies.](https://pubmed.ncbi.nlm.nih.gov/28027657/). *The American journal of sports medicine*, 2017. DOI: 10.1177/0363546516680607. ## An exam can help when soreness stays Tell the licensed clinic staff where it hurts, when it began, and what you've tried. Bring your medicine names and any old joint reports. Book a free consultation: --- Straight help for a sore joint in Glendale. See why a joint aches, steps you can try, warning signs, and regenerative choices near Glendale. Clear guidance on aching joints, simple care, warning signs, and nearby visits for Glendale readers. This Glendale evidence desk is operated by the same owners who run the QC Kinetix Phoenix-area clinics it recommends. © 2026 Glendale Regen Monitor. Educational information only; individual decisions require medical assessment.